Investor Relations

Investor News
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
December 12, 2024 Financial Results [Delayed]Non-consolidated Financial Results for Three Months Ended October 31, 2024 [Japanese GAAP] 
December 12, 2024 Timely Disclosure Information [Delayed]StemRIM Announces Selection for the AMED Project “FY2024 Project for Fundamental Technology Development toward Industrialization of Regenerative Medicine and Gene Therapy” 
December 11, 2024 Timely Disclosure Information StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation 
December 09, 2024 Timely Disclosure Information StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure Caused Thereby 
December 05, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide, Redasemtide 
November 13, 2024 Timely Disclosure Information StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock 
November 05, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide 
October 31, 2024 Timely Disclosure Information Presentation Material for Business Plan and Growth Potential 
September 25, 2024 Timely Disclosure Information Notice Regarding Appointment of Director Candidates 
September 25, 2024 Timely Disclosure Information StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators 
September 13, 2024 Financial Results Presentation Materials Presentation Materials Financial Results for the the Fiscal Year Ended July 31, 2024 
September 11, 2024 Timely Disclosure Information Notice Regarding Differences between Non-consolidated Result s for Fiscal Year Ended July 31, 2024 and those for Previous Fiscal Year 
September 11, 2024 Financial Results Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2024 [Japanese GAAP] 
August 09, 2024 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employees and External Collaborator 
August 08, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in China for Peripheral Peptides of the HMGB1 Fragment Peptide, Redasemtide 
July 26, 2024 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to Employees 
July 26, 2024 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to Directors 
July 25, 2024 Timely Disclosure Information StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Directors 
July 25, 2024 Timely Disclosure Information StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employees 
July 25, 2024 Timely Disclosure Information StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employees and External Collaborator 
July 08, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in Japan for Stem Cell Gene Therapy for Dystrophic Epidermolysis Bullosa 
July 01, 2024 IR News Noteice of Extraordinary General Meeting of Shareholders 
June 17, 2024 Timely Disclosure Information StemRIM Announces Patent Registration (Australia) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction 
June 12, 2024 Financial Results Non-consolidated Financial Results for the Nine Months Ended April 30, 2024 [Japanese GAAP] 
May 08, 2024 Timely Disclosure Information StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease) 
March 21, 2024 IR News StemRIM Announces Symposium on “Regeneration-Inducing Medicine” at the 23rd Congress of the Japanese Society for Regenerative Medicine 
March 15, 2024 Financial Results Presentation Materials Presentation Materials for Six Months Ended January 31, 2024 
March 13, 2024 Financial Results Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP] 
March 13, 2024 Timely Disclosure Information StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy 
February 29, 2024 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators 
February 15, 2024 Timely Disclosure Information StemRIM Announces Patent Registration (Japan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, and Disseverance Osteochondritis 
February 14, 2024 Timely Disclosure Information StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborators 
January 31, 2024 Timely Disclosure Information StemRIM Announces Patent Registration (Russia) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders (Traumatic Cartilage Deficiency Syndrome, Osteoarthritis, Disseverance Osteochondritis, etc.) 
December 28, 2023 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborator 
December 13, 2023 Financial Results Non-consolidated Financial Results for the Three Months Ended October 31, 2023[Japanese GAAP] 
December 13, 2023 Timely Disclosure Information StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborator 
December 06, 2023 Timely Disclosure Information StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation 
December 04, 2023 Timely Disclosure Information StemRIM Announces Conclusion of Agreement for the Initiation of a Phase2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy 
November 16, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023 
November 16, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock 
October 27, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Change of Representative Directors 
September 28, 2023 Timely Disclosure Information StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employee and External collaborator 
September 28, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers, Employees, and External Collaborators 
September 20, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Employee 
September 20, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Director 
September 19, 2023 Timely Disclosure Information [Derayed]Presentation Material, Financial Results for the Fiscal Year Ended July 31, 2023 
September 19, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employee and External collaborator 
September 19, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employee 
September 19, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Director 
September 13, 2023 Financial Results Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2023[Japanese GAAP] 
September 13, 2023 Investor Calendar
Announcement of Financial Results for the Fiscal Year Ended July 31, 2023
September 06, 2023 Timely Disclosure Information StemRIM Announces Patent Registration (US) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy (Dilated Cardiomyopathy, Ischemic Cardiomyopathy, and Hypertensive Cardiomyopathy) 
September 04, 2023 Timely Disclosure Information StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction 
July 31, 2023 Timely Disclosure Information StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Japan) 
July 26, 2023 Investor Calendar
Extraordinary General Meeting of Shareholders
July 25, 2023 Timely Disclosure Information StemRIM Announces the Initiation of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Europe, China) 
July 18, 2023 Timely Disclosure Information StemRIM Announces Patent Registration (Korea) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction 
June 19, 2023 Financial Results [Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2023[Japanese GAAP] 
June 14, 2023 Investor Calendar
Announcement of Financial Results for the Nine Month Ended April 30, 2023
June 01, 2023 IR News StemRIM Announces Exhibiting at the “BIO International Convention 2023” and Participating in the “Jefferies 2023 Global Healthcare Conference New York” 
May 24, 2023 Timely Disclosure Information StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide) 
May 22, 2023 Timely Disclosure Information StemRIM Announces Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease (Additional Report) 
May 19, 2023 Timely Disclosure Information [Delayed]StemRIM Announces Patent Registration (Taiwan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction 
May 16, 2023 IR News StemRIM Announces Publication of Scientific Articles for Stem Cell Gene Therapy (PJ5) 
April 28, 2023 Timely Disclosure Information StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke 
April 11, 2023 Timely Disclosure Information [Delayed] StemRIM Announces Preliminary Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease 
April 11, 2023 Timely Disclosure Information [Delayed] Notice of Earnings Forecasts for the Fiscal Year Ending July 31, 2023 
April 11, 2023 Timely Disclosure Information [Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke 
March 16, 2023 Financial Results [Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2023[JapaneseGAAP] 
March 08, 2023 Investor Calendar
Announcement of Financial Results for the Six Month Ended January 31, 2023
December 14, 2022 Investor Calendar
Announcement of Financial Results for the Three Month Ended October 31, 2022
December 14, 2022 Financial Results [Delayed]Non-consolidated Financial Results for the Three Months Ended October 31, 2022[JapaneseGAAP] 
October 26, 2022 Investor Calendar
Annual General Meeting of Shareholders for the fiscal year ending July 2022
September 08, 2022 Investor Calendar
Announcement of Financial Results for the Fiscal Year Ended July 31, 2022
September 08, 2022 Financial Results [Delayed]Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2022[Japanese GAAP] 
June 09, 2022 Investor Calendar
Announcement of Financial Results for the Nine Month Ended April 30, 2022
June 09, 2022 Financial Results [Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2022[Japanese GAAP] 
March 16, 2022 Financial Results [Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2022[JapaneseGAAP] 
March 10, 2022 Investor Calendar
Announcement of Financial Results for the Six Month Ended January 31, 2022
December 12, 2021 Financial Results [Delayed]Non-consolidated Financial Results for the Three Months Ended October 31, 2021[JapaneseGAAP] 
December 09, 2021 Investor Calendar
Announcement of Financial Results for the Three Month Ended October 31, 2021
October 27, 2021 Investor Calendar
Annual General Meeting of Shareholders for the fiscal year ending July 2021
September 09, 2021 Financial Results [Delayed]Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2021[Japanese GAAP] 
September 09, 2021 Investor Calendar
Announcement of Financial Results for the Fiscal Year Ended July 31, 2021
June 10, 2021 Investor Calendar
Announcement of Financial Results for the Nine Month Ended April 30, 2021
June 10, 2021 Financial Results [Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2021[Japanese GAAP] 
March 11, 2021 Investor Calendar
Announcement of Financial Results for the Six Month Ended January 31, 2021
March 11, 2021 Financial Results [Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2021[Japanese GAAP] 
December 12, 2020 Financial Results [Delayed]Non-consolidated Financial Results for the Three Months Ended October 31, 2020[Japanese GAAP] 
December 09, 2020 Investor Calendar
Announcement of Financial Results for the Three Month Ended October 31, 2020
October 28, 2020 Investor Calendar
Annual General Meeting of Shareholders for the fiscal year ending July 2020
September 10, 2020 Financial Results [Delayed]Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2020[Japanese GAAP] 
September 10, 2020 Investor Calendar
Announcement of Financial Results for the Fiscal Year Ended July 31, 2020
June 11, 2020 Investor Calendar
Announcement of Financial Results for the Nine Month Ended April 30, 2020
June 11, 2020 Financial Results [Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2020[Japanese GAAP] 
March 11, 2020 Financial Results [Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2020[Japanese GAAP] 
March 11, 2020 Investor Calendar
Announcement of Financial Results for the Six Month Ended January 31, 2020
StemRIM > Investor Relations > Investor News